WebJan 7, 2024 · Thrombotic microangiopathy (TMA) is a disease of multiple etiologies manifesting as non-immune hemolytic anemia, thrombocytopenia, and organ dysfunction including AKI. Laboratory findings include elevated indirect bilirubin and LDH levels, depressed serum haptoglobin values, and schistocytes on peripheral blood smear. WebPlatinum, the Synergistic Drug: From Clinical Evidence to Laboratory Suggestions.- Chemotherapy of Mammary Cancer with Anthracyclins and Alkylators.- The Pharmaceutical Stabilization of the Clinical Anticancer Drug Dach-Platinum-TMA (NSC271674).- A Clinical Study of Reduced Glutathione as a Protective Agent Against Cisplatin-Induced Toxicity.-
High-dose Carboplatin/Etoposide/Melphalan increases risk of …
WebApr 6, 2024 · Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy (TMA) characterized by the triad of ... cisplatin, bleomycin, and 5-FU, all of which have been shown to cause HUS [13]. ... Reese JA, Terrell DR, Vesely SK, George JN: Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015, … WebJul 1, 2024 · Platinum-based drugs are alkylating agents frequently used in Oncology. Nephrotoxicity, whereas uncommon, is a major adverse effect [40]. Cisplatin-induced … slow cooker rump roast
Cisplatin: Package Insert - Drugs.com
WebThrombotic microangiopathy (TMA) is a serious toxicity associated with a small number of antineoplastic agents. A case report of a patient with probable cisplatin and bleomycin … WebSep 1, 2024 · Cisplatin-induced TMA is associated with poor outcomes and does not have an established treatment.22 Mild proteinuria (<500 mg/d) can also be observed after treatment with high-dose cisplatin and is primarily of tubular origin.16,23 Table 1. Nephrotoxicity Associated With Platinum-Based Chemotherapeutics WebApr 1, 2024 · Drug-induced TMA (DI-TMA) is a thrombotic microangiopathy (TMA) caused by certain drugs,usually managed by drug discontinuation and supportive measures. Data on the use of complement-inhibition with eculizumab in DI-TMA is scarce, and its benefit in cases of severe or refractory DI-TMA is unclear. slow cooker rp